Sten Stovall
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Modus CEO On Its Plans For An At-Home Injectable For Sickle Cell Crises
Modus Therapeutics has begun a Phase I study with subcutaneously administered sevuparin. Its CEO says this new formulation of its lead asset has the potential to be self-administered by sickle cell disease patients at home for the treatment of vaso-occlusive crises.
Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes
Novo Nodisk's CSO says FDA approval of extended half-life Factor VIII Esperoct treatment for people with hemophilia A will give more choice to those patients and "effectively completes" the Danish group's hitherto R&D efforts based on clotting factor deficiencies.
Pioneering Gyroscope Therapeutics Aims To Develop One-Time Gene Therapy For AMD
Gyroscope Therapeutics, which aims to develop genetically defined therapies for a range of eye diseases, has begun dosing in a Phase I/II clinical trial in dry age-related macular degeneration using its lead candidate.
Troubled Realm Therapeutics Selling Assets, Delisting From London AIM
US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.
Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
US Rights Deal Will Make Proleukin Clinigen's Biggest Product
Clinigen's planned purchase of US rights to Proleukin will give it global ownership of the IL-2 drug.